Technical Analysis for OCUL - Ocular Therapeutix, Inc.

Grade Last Price % Change Price Change
grade D 4.45 0.23% 0.01
OCUL closed up 0.23 percent on Friday, September 13, 2019, on 45 percent of normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Up
See historical OCUL trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
50 DMA Resistance Bearish 0.23%
Bearish Engulfing Bearish 0.23%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.23%
50 DMA Resistance Bearish -1.98%
Crossed Above 20 DMA Bullish 0.23%
Fell Below 20 DMA Bearish 3.25%
Narrow Range Bar Range Contraction 3.25%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.60%

Older signals for OCUL ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Ocular Therapeutix, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapies based on its proprietary hydrogel platform technology for treating eye diseases and conditions. The company offers ReSure Sealant, a topical liquid hydrogel that creates a sealant to prevent post-surgical leakage from clear corneal incisions made during cataract surgery Its lead product candidates comprise OTX-DP, which is in Phase III clinical trials for the treatment of post-surgical ocular inflammation and pain; and OTX-TP that is in Phase II clinical trials for the treatment of glaucoma and ocular hypertension. The company's earlier stage product candidates include OTX-DP, which is in Phase II clinical trials for the treatment of allergic conjunctivitis; OTX-MP that has completed Phase I clinical trials for the treatment of bacterial conjunctivitis; and Anti-VEGF hydrogel depot, which is in preclinical testing for the treatment of wet AMD. Ocular Therapeutix, Inc. sells its ReSure Sealant through a network of independent medical device distributors in the United States. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.
Health Medical Specialties Pain Clinical Trial Glaucoma Cataract Treatment Of Glaucoma Eye Diseases Incisions Allergic Conjunctivitis Allergology Cataract Surgery Ocular Hypertension Post Surgical Ocular Inflammation
Is OCUL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 7.31
52 Week Low 2.35
Average Volume 667,201
200-Day Moving Average 4.2025
50-Day Moving Average 4.5896
20-Day Moving Average 4.365
10-Day Moving Average 4.369
Average True Range 0.2729
ADX 15.02
+DI 22.9265
-DI 16.3993
Chandelier Exit (Long, 3 ATRs ) 4.0313
Chandelier Exit (Short, 3 ATRs ) 4.6387
Upper Bollinger Band 4.7915
Lower Bollinger Band 3.9385
Percent B (%b) 0.6
BandWidth 19.54181
MACD Line -0.0133
MACD Signal Line -0.0476
MACD Histogram 0.0343
Fundamentals Value
Market Cap 129.3 Million
Num Shares 29.1 Million
EPS -2.15
Price-to-Earnings (P/E) Ratio -2.07
Price-to-Sales 88.04
Price-to-Book 3.48
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.65
Resistance 3 (R3) 4.64 4.56 4.62
Resistance 2 (R2) 4.56 4.51 4.57 4.61
Resistance 1 (R1) 4.51 4.48 4.54 4.52 4.60
Pivot Point 4.43 4.43 4.44 4.43 4.43
Support 1 (S1) 4.37 4.38 4.40 4.38 4.30
Support 2 (S2) 4.29 4.34 4.30 4.29
Support 3 (S3) 4.24 4.29 4.28
Support 4 (S4) 4.25